Page last updated: 2024-08-21

alpha-aminopyridine and fostamatinib

alpha-aminopyridine has been researched along with fostamatinib in 130 studies

Research

Studies (130)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (7.69)	29.6817
2010's	94 (72.31)	24.3611
2020's	26 (20.00)	2.80

Authors

Authors	Studies
Banquerigo, ML; Brahn, E; Chang, B; Grossbard, EB; Lau, A; Payan, DG; Pine, PR; Schoettler, N; Wang, S; Zhao, F	1
Sheridan, C	1
Bahjat, FR; Baluom, M; Cassafer, G; Chang, B; Daikh, DI; Grillo, S; Grossbard, EB; Payan, DG; Pine, PR; Reitsma, A; Zhao, FF	1
Burgos-Vargas, R; Dikranian, AH; Grossbard, E; Kavanaugh, A; Medrano-Ramirez, G; Morales-Torres, JL; Murphy, FT; Musser, TK; Straniero, N; Vicente-Gonzales, AV; Weinblatt, ME	1
Bussel, JB; Crow, AR; Grossbard, E; Lazarus, AH; Podolanczuk, A	1
Baluom, M; Clemens, GR; Grossbard, EB; Lech, JW; Magness, SH; Masuda, ES; Schroeder, RE; Taylor, VC; Weaver, EV	1
Bajpai, M	1
Chow, CW; Lau, CW; Sanderson, MP; Schnapp, A	1
Downing, JR	1
Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM	1
Bhangal, G; Chawanasuntorapoj, R; Cook, HT; Masuda, ES; McDaid, JP; Pusey, CD; Smith, J; Tam, FW	1
Cripe, LD; De Vos, S; Friedberg, JW; Gregory, SA; Johnston, PB; Lacasce, A; Leonard, JP; Levy, R; Lowe, AM; Schaefer-Cutillo, J; Sharman, J; Shipp, MA; Sinha, R; Sterba, MP; Sweetenham, J; Vose, JM	1
Bahjat, FR; Deng, GM; Liu, L; Pine, PR; Tsokos, GC	1
Opar, A	1
Baluom, M; Bhamidipati, S; Clough, J; Grossbard, E; Lau, DT; Li, W; Park, G; Singh, R; Sweeny, DJ	1
Grossbard, E; Lau, DT; Li, W; Sweeny, DJ	1
Dalle Lucca, JJ; Lapchak, PH; Pamuk, ON; Pine, P; Rani, P; Tsokos, GC	1
Catalano, G; Chew, C; Clynes, R; Colonna, L; D'Agati, V; Masuda, ES; Reizis, B; Schmitz, J; Tarakhovsky, A; Thomas, JW; Wong, FS	1
Bennardo, S; Efremov, DG; Laurenti, L; Leone, G; Longo, PG; Perlas, E; Suljagic, M	1
Genovese, MC; Grossbard, EB; Kavanaugh, A; Magilavy, DB; Musser, TK; Weinblatt, ME	1
Colbert, RA; Rivera, J	1
Kobayashi, A; Okamoto, H	1
Andreu, JL; Otón, T; Silva-Fernández, L	1
Baluom, M; Grossbard, EB; Lau, DT; Samara, E	1
Boers, M	1
DiCarlo, J; Genovese, MC; Grossbard, EB; Kavanaugh, A; Magilavy, DB; O'Brien, M; Peterfy, C; Weinblatt, ME; White, ML	1
Kapoor, S	1
Scheinecker, C; Smolen, JS	1
Bosch, X; Gómez-Puerta, JA	1
Efremov, DG; Laurenti, L	1
Bode, C; Buchner, M; Colberg, C; Eisele, S; Hilgendorf, I; Hoppe, N; Lozhkin, A; Ortiz-Rodriguez, A; Remer, I; Schmitz, J; Stachon, P; von zur Muhlen, C; Willecke, F; Wolf, D; Zeschky, K; Zirlik, A; Zirlik, K; zur Hausen, A	1
Scott, DL	1
Regens, AL; Yazici, Y	1
Burger, JA	1
Barr, PM; Friedberg, JW; Jung, J; Kelly, JL; Roger, J; Rosenberg, AF; Sanz, I; Schaefer-Cutillo, J; Wei, C	1
Buchner, M; Fisch, P; Gerlach, UV; Hechinger, AK; Leonhardt, F; Prinz, G; Reichardt, W; Schmitt-Gräff, A; Zeiser, R; Zirlik, K	1
Fleischmann, R	1
Del Pino-Montes, J; Gómez-Castro, S; Hidalgo, C; López, R; Montilla Morales, C; Sánchez, M	1
Dalle Lucca, JJ; Ioannou, A; Kannan, L; Lapchak, PH; Pamuk, ON; Pine, P; Rani, P; Tsokos, GC	1
Wiestner, A	2
Morales-Torres, J	1
Baluom, M; Grossbard, EB; Lau, DT; Mant, T	1
Steiger, B; Yazici, Y	1
Kawabata, D; Kitagori, K	1
Genovese, MC; Grossbard, EB; Jones, DA; Kavanaugh, A; Magilavy, DB; Musser, TK; Weinblatt, ME	1
Burmester, GR; Feist, E	1
Barr, PM; Friedberg, JW; Herman, SE; Liu, D; McAuley, EM; Wiestner, A	1
Esquivel, CO; Hatton, O; Krams, SM; Lambert, SL; Martinez, OM; Natkunam, Y; Phillips, LK; Vaysberg, M	1
Alarcon, S; Collins, J; Doroshow, JH; Kinders, RJ; Kummar, S; Lee, MJ; Park, SR; Pfister, T; Piekarz, R; Speranza, G; Steinberg, SM; Trepel, JB; Wang, L; Wright, JJ	1
McInnes, IB; Nijjar, JS; Siebert, S; Tindell, A	1
Chihara, K; Honjo, C; Kimura, Y; Sada, K; Takeuchi, K	1
Fan, L; Han, TT; Li, JY; Xu, W	1
Fu, J; Herzog, B; Hess, PR; Jakus, Z; Kahn, ML; Lu, M; Makinen, T; Nieswandt, B; Oliver, G; Rawnsley, DR; Sweet, DT; Xia, L; Yang, Y	1
Braddock, M; Coverley, L; Curwen, JO; Duffy, P; Glaves, P; Harmer, AR; Huby, R; Lamm Bergström, E; Lengel, D; Musgrove, H; Philp, K; Prior, H; Skinner, M	1
Scott, DL; Scott, IC	1
Date, M; Fujimoto, M; Hamaguchi, Y; Hasegawa, M; Hau, KT; Kimura, H; Le Huu, D; Matsushita, T; Takehara, K	1
Bhangal, G; Cook, HT; Jackson, WD; Masuda, ES; McAdoo, SP; McDaid, JP; Pusey, CD; Reynolds, J; Smith, J; Tam, FW; Tanna, A	1
Beyene, J; Danska, JS; Grandal, I; Guidos, CJ; Hitzler, JK; Kowalski, PE; Matei, IR; Minden, MD; Nutter, LM; Papp, E; Perova, T	1
Boström, E; Hanze, E; Martin, P; Öhrn, F; Sandström, M; Wählby-Hamrén, U	1
Benson, RA; Braddock, M; Brewer, JM; Butcher, JP; Garside, P; McInnes, IB; McQueenie, R; Platt, AM	1
Genovese, MC; Greenwood, M; Ho, M; Nasonov, E; Oemar, B; Stoilov, R; Taylor, PC; Vencovsky, J; Weinblatt, M	1
Genovese, MC; Ho, M; Hollis, S; Kavanaugh, A; Leon, G; Millson, DS; Rosiak-Jedrychowicz, K; van der Heijde, D; Wang, M; Weinblatt, ME	1
Benhamou, C; Duffield, EL; Fudman, E; Genovese, MC; Kavanaugh, A; Keystone, EC; Lampl, K; O'Brien, C; Poiley, J; Spindler, AJ; van der Heijde, DM; Weinblatt, ME	1
Cox, E; Hamrén, B; Hamrén, UW; Kågedal, M; Maringwa, J; Martin, P	1
Niemann, CU	1
Baran-Marszak, F; Bernard, S; Cymbalista, F; Danglade, D; Gardano, L; Gribben, J; Laguillier, C; Lazarian, G; Ledoux, D; Marzec, J; Roger, C; Thieblemont, C; Varin-Blank, N	1
Abreu, G; Jedrychowicz-Rosiak, K; Kitas, GD; Miller, JL; Nakov, R; Panfilov, S; Vencovsky, J; Wang, M; Weinblatt, ME; White, WB	1
Blum, S; Lamb, D; Thaler, E; Wex, E	1
Pettitt, AR; Slupsky, JR; Till, KJ	1
Ansell, SM; Baladandayuthapani, V; Bjorklund, CC; Jones, RJ; Kuiatse, I; Lin, HY; Orlowski, RZ; Shah, JJ; Thomas, SK; Treon, SP; Wang, M; Weber, DM; Yang, G; Zhang, XD	1
Alexander, KA; Allen, JL; Antin, JH; Blazar, BR; Chao, NJ; Clynes, RA; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Luznik, L; MacDonald, KP; Maillard, I; Murphy, WJ; Panoskaltsis-Mortari, A; Paz, K; Poe, JC; Ritz, J; Sarantopoulos, S; Serody, JS; Soiffer, RJ; Taylor, PA; Vulic, A	1
Aksit, H; Ayvaz, S; Can, G; Can, H; Demirtas, S; Karaca, T; Korkmaz, U; Kurt, M; Yilmaz, B	1
Askling, J; Berglind, N; Franzén, S; Greenberg, JD; Ho, M; Holmqvist, M; Horne, L; Lampl, K; Michaud, K; Nyberg, F; Pappas, DA; Reed, G; Symmons, D; Tanaka, E; Tran, TN; Verstappen, SM; Wesby-van Swaay, E; Yamanaka, H	1
Cheung, SY; Gillen, M; Han, D; Martin, P; Yen, M	1
Baluom, M; Brealey, C; Elsby, R; Gillen, M; Lau, D; Mant, T; Martin, P; Millson, D; Oliver, S	1
Gillen, M; Marbury, T; Martin, P; Millson, D; Oliver, S	1
Elsby, R; Fenner, K; Martin, P; Sharma, P; Surry, D	1
Ardeshna, KM; Bartlett, NL; Blum, KA; Flinn, IW; Flowers, CR; Friedberg, JW; LaCasce, AS; Mitchell, P; Shustov, AR; Skolnik, JM; Thress, KS; Zheng, F	1
Baluom, M; Brealey, C; Craven, K; Gillen, M; Grossbard, EB; Lau, D; Mant, T; Martin, P; Millson, D; Oliver, S; Sweeny, D	1
Brealey, C; Elsby, R; Gillen, M; Holmes, V; Martin, P; Mathews, D; Oliver, S; Ritter, J; Severin, P; Surry, D	1
Anto-Michel, N; Blanz, KD; Bode, C; Braddock, M; Dufner, B; Geis, S; Gerhardt, LM; Gilsbach, R; Härdtner, C; Hawley, S; Heidt, T; Hein, L; Hergeth, SP; Hilgendorf, I; Hoppe, N; Kornemann, J; Libby, P; Lindau, A; McPheat, W; Robbins, CS; Stachon, P; Swirski, FK; von zur Mühlen, C; Willecke, F; Wolf, D; Zirlik, A; Zou, J	1
Ho, M; Jenkins, M; Landewé, R; Markusse, IM; van der Heijde, D; Wolterbeek, R	1
Devkota, AR; Ghimire, DK; Kunwar, S	1
Duffy, P; Hall, AP; Mitchard, T; Rolf, MG; Stewart, J	1
Brealey, C; Gillen, M; Lau, D; Leese, P; Martin, P; Millson, D; Oliver, S; Surry, D; Sweeny, D	1
Jenkins, M; Wason, JM	1
Flanagan, T; Gillen, M; Kruusmägi, M; Lisbon, E; Martin, P; Mathews, D	1
Bowes, MA; Buonaccorsi, G; DiCarlo, J; Guillard, G; Ho, M; Jenkins, M; Kellner, H; Nordenmark, LH; Parker, GJM; Peterfy, C; Roberts, C; Taylor, PC; Waterton, JC	1
Dholakia, S; Fildes, JE; Friend, PJ	1
Casellato, A; Macaccaro, P; Mandato, E; Nunes, SC; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Visentin, A; Zaffino, F	1
Bussel, JB; Lee, EJ; McDonald, V; Newland, A	1
Giovannini, M; Niscola, P; Scaramucci, L	1
Bay-Jensen, AC; Braddock, M; Gantzel, T; Graham, E; Jenkins, MA; Karsdal, MA; Kjelgaard-Petersen, CF; Musa, K; Platt, A; Slynn, G; Thudium, CS; Weinblatt, ME	1
Arnold, DM; Bussel, J; Cooper, N; Duliege, AM; Grossbard, E; Hellmann, A; Homenda, W; Khalafallah, AA; Markovtsov, V; Mayer, J; Sivcheva, L; Treliński, J; Windyga, J; Zaja, F; Zayed, H	1
Markham, A	1
McAdoo, S; Tam, FWK	1
Arnold, DM; Boxer, MA; Bussel, JB; Cooper, N; Duliege, AM; Mayer, J; Tong, S; Zayed, H	1
Berliner, N; Connell, NT	1
Gebru, T; Moore, DC; Muslimani, A	1
Al-Horani, RA; Clemons Bankston, P	1
Hussar, DA	1
Accordi, B; Basso, G; Bresolin, S; Cortese, G; Mariotto, E; Porcù, E; Serafin, V; Veltri, G	1
Bussel, JB; Izak, M; Lee, EJ	1
Chen, S; Lin, D; Liu, Y; Peng, H; Wang, J; Wang, L; Wang, Y; Xiao, L; Xu, Y; Yang, K	1
Hu, D; Shi, W; Yu, M; Zhang, B; Zhang, L	1
Kapur, R	1
Chancharoenthana, W; Issara-Amphorn, J; Leelahavanichkul, A; Visitchanakun, P	1
McDonald, V; Newland, A	1
Stebbing, J; Tabassum, N; Zhang, H	1
Iwata, S; Millson, D; Nakayamada, S; Tanaka, Y	1
Babyak, A; Chertow, DS; Childs, RW; Davey, RT; Ramos-Benitez, MJ; Randazzo, D; Stein, SR; Strich, JR; Suffredini, AF	1
Boccia, R; Boxer, MA; Bussel, JB; Cooper, N; Ghanima, W; Hill, QA; Sholzberg, M; Tarantino, MD; Todd, LK; Tong, S	1
Gernsheimer, T; Ghanima, W; Kuter, DJ	1
Almonte, M; Charania, A; Cherlin, S; Cook, L; Cooke, G; Cooper, N; Cornelius, V; Innes, AJ; Katsarou, A; Kon, OM; Milojkovic, D; Phillips, R; Pilay, C; Shturova, T; Thursz, M; Turner, R; Vergis, N; Wason, J; Willicombe, M; Youngstein, T	1
Paik, J	1
Allegra, A; Caserta, S; Innao, V; Musolino, C; Zaccuri, AM	1
Bandyopadhyay, SS; Basu, S; Bose, D; Chatterjee, P; Halder, AK; Nasipuri, M; Saha, S	1
Ahmad, K; Aryal, S; Aue, G; Battle, E; Brown, AW; Chakraborty, M; Chertow, DS; Childs, RW; Cohen, J; Collins, AC; Colton, B; Davey, RT; Erb-Alvarez, J; Hays, R; Joo, J; Khangoora, V; Kim, IH; King, CS; Kyte, JJ; Migdady, Y; Nathan, SD; Olivier, KN; Ramos-Benitez, MJ; Reger, R; Rivero, J; Samour, M; Shalhoub, R; Shlobin, O; Strich, JR; Suffredini, AF; Tian, X; Valdez, J; Warner, S; Wong, S	1
Aarts, MJB; Eble, JA; Fernandez, DI; Heemskerk, JWM; Kuijpers, MJE; Tullemans, BME; van der Meijden, PEJ; Veninga, A	1
Agajanian, R; Arnold, DM; Boxer, MA; Broome, CM; Choi, M; Field, JJ; Kuter, DJ; Murakhovskaya, I; Numerof, R; Rogers, KA; Tong, S	1
Abdel-Hakeem, M; Abrams, CS; Alanio, C; Apostolidis, SA; Baxter, AE; Belman, J; Chen, Z; Dougherty, J; Dunbar, D; Frank, I; Giannini, HM; Giles, JR; Goel, RR; Gouma, S; Greenplate, AR; Hensley, SE; Huang, AC; Huang, YJ; Ittner, CAG; Kuthuru, O; Manne, S; Mathew, D; Meyer, NJ; Oldridge, DA; Pattekar, A; Poncz, M; Rauova, L; Reilly, JP; Sarkar, A; Suzuki, A; Vella, LA; Weiderhold, B; Weisman, AR; Wherry, EJ; Wu, JE; Zhao, L	1
Cao, Z; Chen, Y; Guo, W; Hu, H; Li, B; Liu, J; Pang, J; Song, M; Song, X; Wang, C; Wang, J; Wang, M; Xing, Y; Yang, H; Yang, J; Yang, P; Zhang, T; Zhang, Z	1
Dierickx, D; Neefs, J	1
Hirota, T; Ieiri, I; Matsukane, R; Suetsugu, K	1
Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP	1
Cooper, N; Ghanima, W; Hill, QA; Kessler, C; Markovtsov, V; Nicolson, PL	1
Brattås, MK; Hatfield, KJ; Hemsing, AL; Reikvam, H; Rye, KP	1
Alyea, EP; Anand, SM; Bracken, SJ; Cardones, AR; Chao, NJ; Choi, T; DiCioccio, RA; Gasparetto, C; Grunwald, MR; Haykal, T; Hennig, T; Horwitz, ME; Jia, W; Kang, Y; Li, Z; Lin, C; Long, GD; Lopez, R; Martin, M; McManigle, WC; Minor, KK; Poe, JC; Quinones, VLP; Rizzieri, DA; Sarantopoulos, S; Sung, AD; Wiggins, K	1

Reviews

31 review(s) available for alpha-aminopyridine and fostamatinib

Article	Year
Syk: a novel target for treatment of inflammation in lung disease. Inflammation & allergy drug targets, 2009, Volume: 8, Issue:2 Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Intercellular Adhesion Molecule-1; Intracellular Signaling Peptides and Proteins; Leukocytes; Lung Diseases, Obstructive; Morpholines; Oxazines; Picornaviridae Infections; Pneumonia, Viral; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Respiratory Mucosa; Rhinovirus; Signal Transduction; Syk Kinase; Virulence; Virus Internalization	2009
Rheumatoid arthritis in 2010: from the gut to the joint. Nature reviews. Rheumatology, 2011, Volume: 7, Issue:2 Topics: Aminopyridines; Animals; Arthritis, Rheumatoid; Glucocorticoids; Humans; Intestines; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Syk Kinase; Th17 Cells	2011
The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:5 Topics: Aminopyridines; Animals; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Lymphoma; Molecular Targeted Therapy; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2011
Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs, 2011, Jun-18, Volume: 71, Issue:9 Topics: Aminopyridines; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Prodrugs; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2011
Promising new treatments for rheumatoid arthritis - the kinase inhibitors. Bulletin of the NYU hospital for joint diseases, 2011, Volume: 69, Issue:3 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinases; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Syk Kinase; Treatment Outcome	2011
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Current hematologic malignancy reports, 2012, Volume: 7, Issue:1 Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Risk Factors; Signal Transduction	2012
Novel small-molecular therapeutics for rheumatoid arthritis. Current opinion in rheumatology, 2012, Volume: 24, Issue:3 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles	2012
[New therapeutic targets in psoriatic arthritis]. Reumatologia clinica, 2012, Volume: 8 Suppl 1 Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antirheumatic Agents; Arthritis, Psoriatic; Bone Remodeling; Clinical Trials, Phase III as Topic; Cyclic AMP; Cytokines; Denosumab; Disease Progression; Drug Resistance; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Janus Kinases; Lymphocyte Activation; Lymphocyte Depletion; Molecular Targeted Therapy; Morpholines; Oxazines; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidines; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha	2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood, 2012, Dec-06, Volume: 120, Issue:24 Topics: Adenine; Aminopyridines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction	2012
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Medical Oncology; Morpholines; Mutation; NF-kappa B; Oxazines; Phosphatidylinositol 3-Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases	2012
Kinase inhibitors for the treatment of rheumatoid arthritis. Bulletin of the NYU hospital for joint diseases, 2012, Volume: 70, Issue:3 Topics: Aminopyridines; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome	2012
[B cell abnormality in systemic lupus erythematosus]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2012, Volume: 35, Issue:6 Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Autoimmunity; B-Cell Activating Factor; B-Lymphocyte Subsets; Clinical Trials as Topic; Humans; Interleukin-10; Lupus Erythematosus, Systemic; Lymphocyte Activation; Lymphocyte Depletion; Molecular Targeted Therapy; Morpholines; Oxazines; Pyridines; Pyrimidines; Rituximab; T-Lymphocytes	2012
Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford, England), 2013, Volume: 52, Issue:8 Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Germany; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Prognosis; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2013
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology (Oxford, England), 2013, Volume: 52, Issue:9 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome	2013
Syk inhibitors. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2013, Volume: 36, Issue:4 Topics: Aminopyridines; Humans; Intracellular Signaling Peptides and Proteins; Mast Cells; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2013
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. Cancer biology & therapy, 2014, Volume: 15, Issue:1 Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment	2014
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? Drugs, 2014, Volume: 74, Issue:4 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Spleen; Treatment Outcome	2014
[Targeted treatment of chronic lymphocytic leukaemia]. Ugeskrift for laeger, 2014, Apr-07, Volume: 176, Issue:15 Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sulfonamides	2014
Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Rheumatology international, 2016, Volume: 36, Issue:8 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines; Treatment Outcome	2016
The use of kinase inhibitors in solid organ transplantation. Transplantation reviews (Orlando, Fla.), 2017, Volume: 31, Issue:3 Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase	2017
Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy, 2018, Volume: 10, Issue:1 Topics: Adult; Aminopyridines; Blood Platelets; Chronic Disease; Humans; Immunotherapy; Morpholines; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Recurrence; Signal Transduction; Syk Kinase	2018
Fostamatinib: First Global Approval. Drugs, 2018, Volume: 78, Issue:9 Topics: Aminopyridines; Anemia, Hemolytic, Autoimmune; Drug Approval; Glomerulonephritis, IGA; Humans; Morpholines; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome	2018
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy. Seminars in nephrology, 2018, Volume: 38, Issue:5 Topics: Aminopyridines; B-Lymphocytes; Capillaries; Cell Proliferation; Cytokines; Glomerulonephritis, IGA; Humans; Inflammation; Mesangial Cells; Molecular Targeted Therapy; Morpholines; Oxazines; Pyridines; Pyrimidines; Receptors, Fc; Signal Transduction; Syk Kinase	2018
Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood, 2019, 05-09, Volume: 133, Issue:19 Topics: Aminopyridines; Clinical Trials, Phase III as Topic; Humans; Morpholines; Oxazines; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines	2019
New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations. International journal of molecular sciences, 2019, Jun-20, Volume: 20, Issue:12 Topics: Aminopyridines; Animals; Cinnamates; Drug Development; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines; Receptors, Thrombopoietin; Small Molecule Libraries; Syk Kinase; Thiazoles; Thiophenes; Thrombocytopenia	2019
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Immunotherapy, 2020, Volume: 12, Issue:18 Topics: Aminopyridines; Humans; Morpholines; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Treatment Outcome	2020
Fostamatinib: A Review in Chronic Immune Thrombocytopenia. Drugs, 2021, Volume: 81, Issue:8 Topics: Aminopyridines; Chronic Disease; Clinical Trials, Phase III as Topic; Humans; Morpholines; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Randomized Controlled Trials as Topic; Syk Kinase	2021
Immune thrombocytopenia: options and new perspectives. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2021, Oct-01, Volume: 32, Issue:7 Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; COVID-19; Histocompatibility Antigens Class I; Humans; Immunosuppressive Agents; Morpholines; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Receptors, Fc; Receptors, Thrombopoietin; SARS-CoV-2; Syk Kinase; Thiazoles; Thiophenes	2021
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients. Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:8 Topics: Adult; Aminopyridines; Humans; Morpholines; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Thrombocytopenia	2022
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406. Clinical pharmacokinetics, 2022, Volume: 61, Issue:7 Topics: Aminopyridines; ATP Binding Cassette Transporter, Subfamily G, Member 2; Humans; Morpholines; Neoplasm Proteins; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines	2022
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets, 2023, Volume: 34, Issue:1 Topics: Aminopyridines; COVID-19; Humans; Oxazines; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Syk Kinase	2023

Trials

32 trial(s) available for alpha-aminopyridine and fostamatinib

Article	Year
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis and rheumatism, 2008, Volume: 58, Issue:11 Topics: Administration, Oral; Adult; Aged; Aminopyridines; Arthritis, Rheumatoid; Double-Blind Method; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2008
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood, 2009, Apr-02, Volume: 113, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aminopyridines; Animals; Disease Models, Animal; Enzyme Inhibitors; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Middle Aged; Morpholines; Oxazines; Pilot Projects; Prodrugs; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome	2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2010, Apr-01, Volume: 115, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cohort Studies; Diarrhea; Disease-Free Survival; Female; Hematologic Diseases; Humans; Hypertension; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Morpholines; Neoplasm Proteins; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Salvage Therapy; Syk Kinase; Treatment Outcome	2010
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. The New England journal of medicine, 2010, Sep-30, Volume: 363, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Statistics, Nonparametric; Syk Kinase; Treatment Outcome	2010
Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. Journal of clinical pharmacology, 2011, Volume: 51, Issue:9 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2011
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis and rheumatism, 2011, Volume: 63, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Inhibitors; Female; Health Status; Humans; Immunologic Factors; Intracellular Signaling Peptides and Proteins; Joints; Male; Middle Aged; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Severity of Illness Index; Syk Kinase; Treatment Outcome; Young Adult	2011
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. British journal of clinical pharmacology, 2013, Volume: 76, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aminopyridines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Food-Drug Interactions; Half-Life; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Morpholines; Oxazines; Pharmaceutical Solutions; Prodrugs; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Suspensions; Syk Kinase; Tablets; Young Adult	2013
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. The Journal of rheumatology, 2013, Volume: 40, Issue:4 Topics: Adult; Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Fatigue; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Morpholines; Motor Activity; Oxazines; Pain; Pain Measurement; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quality of Life; Severity of Illness Index; Syk Kinase; Treatment Outcome	2013
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cohort Studies; Colorectal Neoplasms; Endothelial Cells; Female; Head and Neck Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasms; Oxazines; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thyroid Neoplasms	2013
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib. Journal of clinical pharmacology, 2014, Volume: 54, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Double-Blind Method; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Models, Biological; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Young Adult	2014
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:12 Topics: Adalimumab; Administration, Oral; Adult; Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Oxazines; Pyridines; Pyrimidines; Severity of Illness Index; Treatment Outcome; Young Adult	2015
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Intracellular Signaling Peptides and Proteins; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome; Young Adult	2014
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist. The Journal of rheumatology, 2014, Volume: 41, Issue:11 Topics: Adult; Aminopyridines; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Morpholines; Oxazines; Patient Safety; Prognosis; Pyridines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha	2014
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA). Journal of clinical pharmacology, 2015, Volume: 55, Issue:3 Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Biotransformation; Clinical Trials, Phase II as Topic; Drug Dosage Calculations; Europe; Humans; Latin America; Linear Models; Markov Chains; Mexico; Morpholines; Oxazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Syk Kinase; Treatment Outcome; United States	2015
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:11 Topics: Adult; Age Factors; Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure Monitoring, Ambulatory; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Morpholines; Multivariate Analysis; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Reference Values; Risk Assessment; Sex Factors; Treatment Outcome	2014
Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies. European journal of clinical pharmacology, 2016, Volume: 72, Issue:1 Topics: Adult; Aminopyridines; Asian People; Double-Blind Method; Erythrocytes; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Young Adult	2016
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. Clinical therapeutics, 2015, Dec-01, Volume: 37, Issue:12 Topics: Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Digoxin; Drug Interactions; Female; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines	2015
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clinical therapeutics, 2015, Dec-01, Volume: 37, Issue:12 Topics: Aminopyridines; Arthritis, Rheumatoid; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines	2015
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European journal of cancer (Oxford, England : 1990), 2016, Volume: 54 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Recurrence; Syk Kinase; Time Factors; Treatment Outcome; United States	2016
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies. Drugs in R&D, 2016, Volume: 16, Issue:1 Topics: Adult; Aminopyridines; Cross-Over Studies; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Humans; Ketoconazole; Male; Microsomes, Liver; Morpholines; Oxazines; Pyridines; Pyrimidines; Rifampin; Verapamil; Young Adult	2016
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. Drugs in R&D, 2016, Volume: 16, Issue:1 Topics: Adult; Aminopyridines; Area Under Curve; Contraceptives, Oral, Combined; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Morpholines; Oxazines; Pyridines; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Warfarin	2016
Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:7 Topics: Adult; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Linear Models; Male; Middle Aged; Morpholines; Oxazines; Pyridines; Pyrimidines; Radiography; Treatment Outcome	2016
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. Clinical pharmacology in drug development, 2016, Volume: 5, Issue:3 Topics: Adult; Aminopyridines; Area Under Curve; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Enzyme Induction; Half-Life; Humans; Male; Middle Aged; Morpholines; Oxazines; Pioglitazone; Pyridines; Pyrimidines; Thiazolidinediones; Young Adult	2016
Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. European journal of clinical pharmacology, 2017, Volume: 73, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aminopyridines; Antacids; Anti-Ulcer Agents; Biological Availability; Cellulose; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Interactions; Female; Food; Humans; Male; Middle Aged; Morpholines; Oxazines; Prodrugs; Pyridines; Pyrimidines; Ranitidine; Solubility; Syk Kinase; Young Adult	2017
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. American journal of hematology, 2018, Volume: 93, Issue:7 Topics: Adult; Aminopyridines; Blood Platelets; Chronic Disease; Humans; Morpholines; Oxazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Splenectomy; Syk Kinase; Treatment Outcome	2018
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. American journal of hematology, 2019, Volume: 94, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Oxazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Time Factors	2019
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford, England), 2021, 06-18, Volume: 60, Issue:6 Topics: Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Asia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Morpholines; Oxazines; Pyridines; Pyrimidines	2021
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. British journal of haematology, 2020, Volume: 190, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Female; Humans; Male; Middle Aged; Morpholines; Oxazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines	2020
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, Apr-12, Volume: 22, Issue:1 Topics: Adult; Aminopyridines; COVID-19 Drug Treatment; Humans; Morpholines; Nitriles; Oxazines; Pandemics; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Respiration, Artificial; Treatment Outcome; Venous Thromboembolism	2021
Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-24, Volume: 75, Issue:1 Topics: Adult; Aminopyridines; COVID-19 Drug Treatment; Double-Blind Method; Hospitalization; Humans; Morpholines; Oxazines; Oxygen; Pyridines; Pyrimidines; SARS-CoV-2; Treatment Outcome	2022
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. American journal of hematology, 2022, 06-01, Volume: 97, Issue:6 Topics: Adult; Aminopyridines; Anemia, Hemolytic, Autoimmune; COVID-19; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines	2022
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease. Transplantation and cellular therapy, 2023, Volume: 29, Issue:3 Topics: Aminopyridines; Animals; Bronchiolitis Obliterans Syndrome; Graft vs Host Disease; Humans; Mice; Neoplasm Recurrence, Local; Oxazines; Pyridines; Steroids; Syk Kinase	2023

Other Studies

67 other study(ies) available for alpha-aminopyridine and fostamatinib

Article	Year
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clinical immunology (Orlando, Fla.), 2007, Volume: 124, Issue:3 Topics: Aminopyridines; Animals; Arthritis, Rheumatoid; Arthus Reaction; Bone Resorption; Collagen Type II; Disease Models, Animal; Female; Immunoglobulin G; Inflammation; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, IgG; Signal Transduction; Syk Kinase; Synovial Fluid; Synovitis	2007
Small molecule challenges dominance of TNF-alpha inhibitors. Nature biotechnology, 2008, Volume: 26, Issue:2 Topics: Aminopyridines; Arthritis, Rheumatoid; Drug Industry; Economic Competition; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines; Tumor Necrosis Factor-alpha; United States	2008
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis and rheumatism, 2008, Volume: 58, Issue:5 Topics: Administration, Oral; Aminopyridines; Animals; Disease Progression; Lupus Erythematosus, Systemic; Mice; Mice, Inbred BALB C; Mice, Inbred NZB; Morpholines; Oxazines; Pyridines; Pyrimidines; Survival Rate; Time Factors	2008
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth defects research. Part A, Clinical and molecular teratology, 2009, Volume: 85, Issue:2 Topics: Abnormalities, Drug-Induced; Aminopyridines; Animals; Cells, Cultured; Embryonic Development; Enzyme Inhibitors; Female; Infertility; Male; Morpholines; Oxazines; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Rabbits; Rats; Reproduction; Toxicity Tests	2009
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs : the investigational drugs journal, 2009, Volume: 12, Issue:3 Topics: Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma; Molecular Structure; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Structure-Activity Relationship; Syk Kinase	2009
Can treating the SYK cell cure leukemia? Cancer cell, 2009, Oct-06, Volume: 16, Issue:4 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine	2009
Proteomic and genetic approaches identify Syk as an AML target. Cancer cell, 2009, Oct-06, Volume: 16, Issue:4 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays	2009
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:2 Topics: Aminopyridines; Animals; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Glomerulonephritis; Interleukin-1beta; Intracellular Signaling Peptides and Proteins; Macrophages; Mesangial Cells; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats; Rats, Inbred WKY; Severity of Illness Index; Signal Transduction; Syk Kinase	2010
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis and rheumatism, 2010, Volume: 62, Issue:7 Topics: Aminopyridines; Animals; Disease Models, Animal; Enzyme Inhibitors; Female; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymph Nodes; Mice; Mice, Inbred MRL lpr; Mice, Knockout; Morpholines; Oxazines; Prodrugs; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Skin Diseases	2010
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:4 Topics: Administration, Oral; Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles	2010
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:7 Topics: Adult; Aminopyridines; Bacteria, Anaerobic; Biotransformation; Gastrointestinal Tract; Humans; In Vitro Techniques; Inactivation, Metabolic; Liver; Male; Microsomes; Morpholines; Oxazines; Prodrugs; Pyridines; Pyrimidines	2010
Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica; the fate of foreign compounds in biological systems, 2010, Volume: 40, Issue:6 Topics: Administration, Oral; Aminopyridines; Animals; Bacteria, Anaerobic; Bile; Carbon Radioisotopes; Feces; Intestines; Intracellular Signaling Peptides and Proteins; Macaca fascicularis; Male; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2010
Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:2 Topics: Aminopyridines; Animals; Complement C3; Enzyme Activation; Enzyme Inhibitors; Immunoglobulin G; Immunoglobulin M; Intestines; Intracellular Signaling Peptides and Proteins; Lung; Mice; Mice, Inbred C57BL; Morpholines; Neutrophil Infiltration; Oxazines; Protein-Tyrosine Kinases; Pulmonary Circulation; Pyridines; Pyrimidines; Receptors, Cell Surface; Reperfusion Injury; Splanchnic Circulation; Syk Kinase	2010
Therapeutic targeting of Syk in autoimmune diabetes. Journal of immunology (Baltimore, Md. : 1950), 2010, Aug-01, Volume: 185, Issue:3 Topics: Aminopyridines; Animals; Cross-Priming; Dendritic Cells; Diabetes Mellitus, Type 1; Female; Gene Targeting; Immunoglobulin G; Immunoglobulin M; Insulin; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mice, Transgenic; Morpholines; Ovalbumin; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Receptors, IgG; Syk Kinase	2010
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Adoptive Transfer; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Separation; Disease Models, Animal; Flow Cytometry; Immunophenotyping; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Syk Kinase	2010
Healing the Syk through kinase inhibitors. The New England journal of medicine, 2010, Sep-30, Volume: 363, Issue:14 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2010
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. The New England journal of medicine, 2011, 01-06, Volume: 364, Issue:1 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Morpholines; Neutropenia; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; src-Family Kinases; Syk Kinase	2011
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. The New England journal of medicine, 2011, 01-06, Volume: 364, Issue:1 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Intracellular Signaling Peptides and Proteins; Methotrexate; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2011
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis and rheumatism, 2011, Volume: 63, Issue:2 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Risk Assessment; Syk Kinase	2011
Comment on "Therapeutic targeting of Syk in autoimmune diabetes". Journal of immunology (Baltimore, Md. : 1950), 2011, Feb-15, Volume: 186, Issue:4 Topics: Aminopyridines; Autoimmune Diseases; Diabetes Mellitus, Type 2; Glomerulonephritis; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Reperfusion Injury; Signal Transduction; Spleen; Syk Kinase	2011
Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA? Nature reviews. Rheumatology, 2011, Volume: 7, Issue:3 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome	2011
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:9 Topics: Administration, Oral; Aminopyridines; Animals; Atherosclerosis; Cell Differentiation; Cell Movement; Cholesterol, Dietary; Inflammation; Intracellular Signaling Peptides and Proteins; Macrophages; Mice; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptors, LDL; Syk Kinase	2011
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clinical immunology (Orlando, Fla.), 2012, Volume: 142, Issue:3 Topics: Aminopyridines; Cell Differentiation; Humans; Interleukin-10; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2012
Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia, 2012, Volume: 26, Issue:7 Topics: Aminopyridines; Animals; Antigen-Presenting Cells; Blotting, Western; Bone Marrow Transplantation; Cell Movement; Cell Proliferation; Cytomegalovirus; Cytomegalovirus Infections; Dendritic Cells; Female; Flow Cytometry; Graft vs Host Disease; Graft vs Leukemia Effect; Intracellular Signaling Peptides and Proteins; Leukemia; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Morpholines; Oxazines; Phosphorylation; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Spleen; Syk Kinase; T-Lymphocytes; Transplantation, Homologous	2012
Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. American journal of physiology. Gastrointestinal and liver physiology, 2012, Jun-15, Volume: 302, Issue:12 Topics: Aminopyridines; Animals; Blood Platelets; Intestinal Mucosa; Intestines; Intracellular Signaling Peptides and Proteins; Lung; Male; Mice; Morpholines; Oxazines; Platelet Count; Platelet Transfusion; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Reperfusion Injury; Syk Kinase	2012
The status of fostamatinib in the treatment of rheumatoid arthritis. Expert review of clinical immunology, 2012, Volume: 8, Issue:7 Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Prodrugs; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase; Treatment Outcome	2012
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia, 2013, Volume: 27, Issue:8 Topics: Aminopyridines; Antineoplastic Agents; Cell Proliferation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction	2013
Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:4 Topics: Aminopyridines; Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Enzyme Activation; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Intracellular Signaling Peptides and Proteins; Lymph Nodes; Lymphoma, B-Cell; Lymphoproliferative Disorders; Male; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphatidylinositol 3-Kinases; Postoperative Complications; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Syk Kinase; Transplantation, Heterologous	2013
Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. The Journal of clinical investigation, 2014, Volume: 124, Issue:1 Topics: Aminopyridines; Animals; Blood Platelets; Fibrin; Hemostasis; Intestines; Intracellular Signaling Peptides and Proteins; Lectins, C-Type; Lymph Nodes; Lymphatic Vessels; Mice; Mice, Knockout; Morpholines; Oxazines; Platelet Aggregation; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Regional Blood Flow; Syk Kinase; Thoracic Duct; Thrombosis; Venous Valves	2014
The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. British journal of pharmacology, 2014, Volume: 171, Issue:9 Topics: Aminopyridines; Animals; Blood Pressure; Cells, Cultured; Humans; Insecta; Male; Mice; Mice, Nude; Molecular Sequence Data; Morpholines; Nitric Oxide; Organ Culture Techniques; Oxazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Signal Transduction; Vascular Endothelial Growth Factor A	2014
Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of dermatological science, 2014, Volume: 74, Issue:3 Topics: Aminopyridines; Animals; B-Lymphocytes; Bone Marrow Transplantation; Chemokines; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Graft vs Host Disease; Intracellular Signaling Peptides and Proteins; Male; Mice, Inbred BALB C; Monocytes; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptors, CXCR4; Scleroderma, Systemic; Syk Kinase; T-Lymphocytes	2014
Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. Journal of the American Society of Nephrology : JASN, 2014, Volume: 25, Issue:10 Topics: Aminopyridines; Animals; Anti-Glomerular Basement Membrane Disease; Antibody Formation; Autoantibodies; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats, Inbred WKY; Spleen; Syk Kinase	2014
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia. Science translational medicine, 2014, May-14, Volume: 6, Issue:236 Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Female; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Male; Mice; Mice, SCID; Morpholines; Mutation; Neoplasm Transplantation; Niacinamide; Oligonucleotide Array Sequence Analysis; Oxazines; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Recurrence; Signal Transduction; Spleen; Syk Kinase; Treatment Outcome	2014
The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells. Rheumatology (Oxford, England), 2015, Volume: 54, Issue:1 Topics: Administration, Oral; Aminopyridines; Animals; Antigen-Antibody Complex; CD4-Positive T-Lymphocytes; Cell Communication; Cell Proliferation; Cells, Cultured; Chemokines; Cytokines; Dendritic Cells; Enzyme Inhibitors; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Models, Animal; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2015
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. International journal of cancer, 2015, Jun-15, Volume: 136, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Aminopyridines; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Cytokines; Female; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Male; Middle Aged; Morpholines; Oxazines; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Syk Kinase; Tumor Cells, Cultured	2015
A novel model of IgE-mediated passive pulmonary anaphylaxis in rats. PloS one, 2014, Volume: 9, Issue:12 Topics: Aminopyridines; Anaphylaxis; Animals; Anti-Asthmatic Agents; Bronchoalveolar Lavage; Bronchoconstriction; Cell Degranulation; Cromolyn Sodium; Dinitrophenols; Disease Models, Animal; Histamine H1 Antagonists, Non-Sedating; Immunoglobulin E; Intracellular Signaling Peptides and Proteins; Loratadine; Lung; Mast Cells; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats; Rats, Wistar; Serum Albumin, Bovine; Syk Kinase	2014
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. Journal of immunology (Baltimore, Md. : 1950), 2015, Mar-01, Volume: 194, Issue:5 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes; Case-Control Studies; Cell Movement; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation, Leukemic; Germinal Center; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lysophospholipids; Morpholines; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Syk Kinase	2015
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jun-01, Volume: 21, Issue:11 Topics: Aminopyridines; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Signal Transduction; Syk Kinase; Waldenstrom Macroglobulinemia	2015
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, Jun-25, Volume: 125, Issue:26 Topics: Aminopyridines; Animals; B-Lymphocytes; Disease Models, Animal; Enzyme Inhibitors; Female; Flow Cytometry; Fluorescent Antibody Technique; Graft vs Host Disease; Humans; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Syk Kinase	2015
The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis. Journal of Crohn's & colitis, 2015, Volume: 9, Issue:10 Topics: Acetic Acid; Aminopyridines; Animals; Colitis; Disease Models, Animal; Intestinal Mucosa; Intracellular Signaling Peptides and Proteins; Male; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Syk Kinase	2015
Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:11 Topics: Aged; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Female; Humans; Male; Middle Aged; Morpholines; Oxazines; Prospective Studies; Pyridines; Pyrimidines; Registries; Research Design; Treatment Outcome	2015
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug metabolism and disposition: the biological fate of chemicals, 2016, Volume: 44, Issue:3 Topics: Aminopyridines; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Drug Interactions; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Liver; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Morpholines; Neoplasm Proteins; Organic Anion Transporters; Oxazines; Pyridines; Pyrimidines; Rosuvastatin Calcium	2016
Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression. Basic research in cardiology, 2016, Volume: 111, Issue:2 Topics: Aminopyridines; Animals; Atherosclerosis; Cell Adhesion; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Female; Intracellular Signaling Peptides and Proteins; Macrophages; Mice; Monocytes; Morpholines; Myelopoiesis; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Random Allocation; Syk Kinase	2016
Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment. Toxicologic pathology, 2016, Volume: 44, Issue:6 Topics: Aminopyridines; Angiogenesis Inhibitors; Animals; Female; Femur Head; Growth Plate; Male; Morpholines; Oxazines; Pyridines; Pyrimidines; Rabbits; Salter-Harris Fractures	2016
Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:10 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Data Collection; Endpoint Determination; Humans; Morpholines; Multicenter Studies as Topic; Oxazines; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. European radiology, 2017, Volume: 27, Issue:9 Topics: Adalimumab; Adult; Aged; Aminopyridines; Arthritis, Rheumatoid; Biomarkers; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Reproducibility of Results; Wrist Joint	2017
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current cancer drug targets, 2018, Volume: 18, Issue:6 Topics: Adenine; Aminopyridines; Apoptosis; Casein Kinase II; Cell Proliferation; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Morpholines; Naphthyridines; Oxazines; Phenazines; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptors, Antigen, B-Cell; Tumor Cells, Cultured	2018
Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia. Immunotherapy, 2018, Volume: 10, Issue:1 Topics: Aminopyridines; Clinical Trials, Phase III as Topic; Humans; Morpholines; Oxazines; Prodrugs; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Recurrence; Syk Kinase	2018
Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:9 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cartilage; Collagen; Drug Development; Drug Discovery; Humans; Morpholines; Oxazines; Pyridines; Pyrimidines; Synovial Membrane; Translational Research, Biomedical	2018
Fostamatinib (Tavalisse) for ITP. The Medical letter on drugs and therapeutics, 2019, Feb-25, Volume: 61, Issue:1566 Topics: Aminopyridines; Drug Interactions; Humans; Morpholines; Oxazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thrombocytopenia	2019
Fostamatinib for the treatment of immune thrombocytopenia in adults. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, May-17, Volume: 76, Issue:11 Topics: Administration, Oral; Aminopyridines; Blood Platelets; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Humans; Morpholines; Oxazines; Platelet Count; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Receptors, Fc; Signal Transduction; Syk Kinase; Treatment Outcome	2019
New Drugs 2019, part 4. Nursing, 2019, Volume: 49, Issue:11 Topics: Aminopyridines; Cinnamates; Drug Approval; Factor Xa; Humans; Macrolides; Morpholines; Oligonucleotides; Oxazines; Pyridines; Pyrimidines; Recombinant Proteins; RNA, Small Interfering; Sisomicin; Tetracyclines; Thiazoles; Thiophenes; United States; United States Food and Drug Administration	2019
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric International journal of molecular sciences, 2019, Dec-07, Volume: 20, Issue:24 Topics: Aminopyridines; Cell Proliferation; Child; Core Binding Factor Alpha 2 Subunit; Cyclohexylamines; Drug Resistance, Neoplasm; Humans; Indazoles; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrimidines; Syk Kinase; Tumor Cells, Cultured	2019
Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). British journal of haematology, 2020, Volume: 189, Issue:2 Topics: Adult; Aged; Aminopyridines; Chronic Disease; Female; Humans; Morpholines; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines	2020
PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. Gene, 2020, Jun-20, Volume: 744 Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin E; Humans; Male; Membrane Proteins; Morpholines; Oncogene Proteins; Oxazines; Prognosis; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines	2020
Identification of prognostic biomarkers and drug target prediction for colon cancer according to a competitive endogenous RNA network. Molecular medicine reports, 2020, Volume: 22, Issue:2 Topics: Aminopyridines; Biomarkers, Tumor; Cell Line, Tumor; Colonic Neoplasms; Computational Biology; Databases, Genetic; Databases, Pharmaceutical; Drug Development; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Genetic Association Studies; Humans; MicroRNAs; Morpholines; Oxazines; Prognosis; Pyridines; Pyrimidines; RNA, Long Noncoding; RNA, Messenger; Survival Analysis; Transcription Factors	2020
Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy. British journal of haematology, 2020, Volume: 190, Issue:6 Topics: Aminopyridines; Humans; Morpholines; Oxazines; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Pyrimidines; Thrombocytopenia	2020
Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis. Journal of innate immunity, 2020, Volume: 12, Issue:6 Topics: Aminopyridines; Animals; Cells, Cultured; Coinfection; Disease Models, Animal; Humans; Inflammation Mediators; Lipopolysaccharides; Lupus Erythematosus, Systemic; Lupus Nephritis; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Oxazines; Pyridines; Pyrimidines; Receptors, IgG; Sepsis; Signal Transduction; Syk Kinase	2020
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury. Cell reports. Medicine, 2020, 11-17, Volume: 1, Issue:8 Topics: Acute Lung Injury; Aminopyridines; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Morpholines; Mucin-1; Pyrimidines; Respiratory Distress Syndrome; SARS-CoV-2; Syk Kinase	2020
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. The Journal of infectious diseases, 2021, 03-29, Volume: 223, Issue:6 Topics: Aminopyridines; COVID-19; COVID-19 Drug Treatment; Extracellular Traps; Humans; Morpholines; Neutrophils; Oxazines; Pyridines; Pyrimidines; SARS-CoV-2	2021
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood, 2021, 05-20, Volume: 137, Issue:20 Topics: Adrenal Cortex Hormones; Adult; Aged; Aminopyridines; Combined Modality Therapy; Disease Management; Drug Substitution; Drug Tolerance; Elective Surgical Procedures; Female; Hemorrhage; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Middle Aged; Morpholines; Preoperative Care; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Remission Induction; Rituximab; Splenectomy; Thrombopoietin; Young Adult	2021
Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate? Methods (San Diego, Calif.), 2022, Volume: 203 Topics: Aminopyridines; Antiviral Agents; ChAdOx1 nCoV-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Molecular Docking Simulation; Morpholines; Pyrimidines; RNA, Viral; SARS-CoV-2	2022
Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment. International journal of molecular sciences, 2021, Oct-18, Volume: 22, Issue:20 Topics: Aminopyridines; Antineoplastic Agents; Blood Platelets; Calcium Signaling; Collagen; Dasatinib; Dose-Response Relationship, Drug; Drug Repositioning; Humans; Morpholines; Phthalazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Thrombosis	2021
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. Frontiers in immunology, 2022, Volume: 13 Topics: Adult; Aminopyridines; Blood Platelets; Cells, Cultured; Complement C5a; COVID-19; Female; Hospitalization; Humans; Male; Morpholines; Platelet Activation; Pyrimidines; Receptor, Anaphylatoxin C5a; Receptors, IgG; SARS-CoV-2; Severity of Illness Index; Signal Transduction; Syk Kinase; Thromboembolism	2022
Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration. Signal transduction and targeted therapy, 2022, 05-13, Volume: 7, Issue:1 Topics: Aminopyridines; Animals; ErbB Receptors; Gefitinib; Inflammation; Mice; Morpholines; Pulmonary Fibrosis; Pyridines; Pyrimidines; Silicosis	2022
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. International journal of molecular sciences, 2022, Jun-23, Volume: 23, Issue:13 Topics: Aminopyridines; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Morpholines; Oxazines; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pyridines; Pyrimidines; Thrombosis; Ticagrelor	2022
Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. International journal of molecular sciences, 2022, Nov-25, Volume: 23, Issue:23 Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Signal Transduction; Syk Kinase	2022